Blueprint Medicines (NASDAQ:BPMC) Earns “Neutral” Rating from Wedbush
Blueprint Medicines (NASDAQ:BPMC – Get Free Report)‘s stock had its “neutral” rating reaffirmed by analysts at Wedbush in a note issued to investors on Monday, Marketbeat reports. They presently have a $129.00 price target on the biotechnology company’s stock, up from their previous price target of $128.00. Wedbush’s target price suggests a potential upside of […]
More Stories
Minerva Academy: Release Date, Plot, Cast, Trailer, and More
Netflix’s latest Italian drama Minerva Academy is currently streaming online on the popular streaming network Netflix. Its original title is...
8 Best Commercial Skylight Companies for US Projects (2026)
Getting commercial daylighting wrong is expensive in a way residential work rarely is. A leaking curb on a house is...
Is Sweet Magnolias Season 6 Renewed? Latest News and Review
Netflix’s romantic drama Sweet Magnolias has finally come to an end. In September 2026, Deadline officially announced that one of...
The Inbetweeners 3: Release Date, Cast, Trailer, and Updates
The Inbetweeners 3 is finally coming back on the popular streaming Network, Netflix. The original four stars of the series,...
7 Essential Components of a Modern Corporate Training Tech Stack
What the seven components need to accomplish Your LMS isn’t obsolete. It may simply need to play one part in...
Climate-ready workplaces in 2026: managing heat, flooding, ice and severe weather
Irish and British workplaces are facing severe weather with increasing frequencies, from heatwares and flash flooding to ice underfoot. Preparing...